In addition, this survival benefit was not consistent in multivariate analyses with validated prognostic markers of melanoma, as the mutational status of neither BRAF nor NRAS was significantly associated with better OS (BRAF: HR for death 0.46, 95% CI 0.20 – 1.07; NRAS: HR for death 0.70, 95% CI 0.33–1.47; Table 6). This evidence concerns the gene BRAF and melanoma.